CNAT - Conatus Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.97
-0.02 (-0.40%)
At close: 4:00PM EDT

4.97 0.00 (0.02%)
After hours: 4:37PM EDT

Stock chart is not supported by your current browser
Previous Close4.99
Open5.01
Bid4.95 x 2200
Ask5.02 x 1200
Day's Range4.88 - 5.07
52 Week Range3.22 - 7.95
Volume727,766
Avg. Volume689,514
Market Cap149.416M
Beta2.31
PE Ratio (TTM)N/A
EPS (TTM)-0.64
Earnings DateJul 31, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.83
Trade prices are not sourced from all markets
  • NASH Space in Focus as Galmed (GLMD) Posts Positive Data
    Zacks8 days ago

    NASH Space in Focus as Galmed (GLMD) Posts Positive Data

    Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.

  • Why Is Conatus Pharmaceuticals (CNAT) Up 4.1% Since Its Last Earnings Report?
    Zacks21 days ago

    Why Is Conatus Pharmaceuticals (CNAT) Up 4.1% Since Its Last Earnings Report?

    Conatus Pharmaceuticals (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates
    Zacks2 months ago

    Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates

    Conatus (CNAT) reports in-line loss in Q1 while revenues beat estimates. Moreover, the top line improves year over year.

  • Associated Press2 months ago

    Conatus: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of 17 cents per share. The results matched Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was also for ...

  • GlobeNewswire2 months ago

    Conatus Pharmaceuticals Reports First Quarter 2018 Financial Results and Program Updates

    SAN DIEGO, May 02, 2018-- Conatus Pharmaceuticals Inc., a biotechnology company focused on the development of novel medicines to treat liver disease, today announced financial results for the first quarter ...

  • Analysts’ Ratings for Amicus and Its Peers in April
    Market Realist2 months ago

    Analysts’ Ratings for Amicus and Its Peers in April

    Amicus Therapeutics (FOLD) is a global patient-focused biotechnology company engaged in developing and commercializing diverse novel treatments for patients with rare metabolic diseases. As of April 2018, of the seven analysts covering Amicus Therapeutics, three have given the stock “strong buy” ratings, three have given it “buy” ratings, and one has given it a “hold” rating. The mean rating for the stock is 1.71 with a target price of $19.93, implying an upside of almost 45% to $13.79 as of its closing on April 24.

  • GlobeNewswire2 months ago

    Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal Hypertension

    Conatus Pharmaceuticals Inc. (CNAT) today announced the completion of enrollment in ENCORE-PH, a Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor. Top-line results from the ENCORE-PH clinical trial are expected in the fourth quarter of 2018. “We were pleased to complete enrollment in the ENCORE-PH clinical trial on schedule,” said David T. Hagerty, M.D., Executive Vice President of Clinical Development at Conatus.

  • What's in the Cards for Conatus (CNAT) This Earnings Season?
    Zacks2 months ago

    What's in the Cards for Conatus (CNAT) This Earnings Season?

    Conatus' (CNAT) might see improvement in Q1 courtesy of its lead candidate emricasan. However, the company's portfolio is devoid of an approved product and its resulting revenues.

  • GlobeNewswire2 months ago

    Conatus Pharmaceuticals to Report First Quarter 2018 Financial Results

    SAN DIEGO, April 25, 2018-- Conatus Pharmaceuticals Inc. today announced that it will report financial results for the first quarter ended March 31, 2018, after the market close on Wednesday, May 2, 2018. ...

  • GlobeNewswire2 months ago

    Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo

    Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the publication1 of results from both in vitro and in vivo studies of its pan-caspase inhibitor, IDN-7314, demonstrating reductions of hepatic tissue factor-driven coagulation. Patients with liver cirrhosis can suffer caspase-driven complications of both excessive bleeding and excessive clotting. The current studies suggest that a pan-caspase inhibitor may have the potential to reduce excessive clotting in patients with severe liver disease.

  • How Analysts Rate Regenxbio and Peers in April 2018
    Market Realist2 months ago

    How Analysts Rate Regenxbio and Peers in April 2018

    Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).

  • Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis
    Zacks2 months ago

    Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis

    The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.

  • ACCESSWIRE2 months ago

    Wired News – Conatus to Demonstrate Impact of Pan-caspase Inhibitor IDN-7314 in Reducing Inflammation and Liver Injury in Mouse Model of PSC at EASL Annual Meeting

    Stock Monitor: Titan Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on Conatus Pharma Inc. (NASDAQ: CNAT ). If you ...

  • GlobeNewswire2 months ago

    Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting

    SAN DIEGO, April 09, 2018-- Conatus Pharmaceuticals Inc., a biotechnology company focused on the development of novel medicines to treat liver disease, today announced an upcoming oral presentation reporting ...

  • Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April
    Market Realist3 months ago

    Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April

    Enanta Pharmaceuticals (ENTA) is a biotechnology company with a chemistry-driven approach. Enanta Pharmaceuticals discovered glecaprevir, a protease inhibitor for the treatment of chronic hepatitis C virus (or HCV). Enanta’s second protease inhibitor under its collaboration with AbbVie is marketed under the tradename Viekera Pak under AbbVie’s initial DAA regimens for the treatment of chronic HCV.

  • Analysts’ Ratings For Acorda Therapeutics in April 2018
    Market Realist3 months ago

    Analysts’ Ratings For Acorda Therapeutics in April 2018

    Acorda Therapeutics (ACOR), a biopharmaceutical company, develops therapies for neurological disorders. Of the ten analysts covering Acorda Therapeutics in April 2018, three have recommended “buy,” six have recommended “hold,” and one has recommended “sell.” Their mean rating for the stock is 2.8, and their target price is $24.78. Of the 20 analysts covering Intercept Pharmaceuticals (ICPT) in April 2018, ten have recommended “buy” or a higher rating, seven have recommended “hold,” and three have recommended “sell.” The mean rating for the stock is 2.5, and its target price is $110.91.

  • Analysts’ Ratings for FibroGen and Its Peers in April 2018
    Market Realist3 months ago

    Analysts’ Ratings for FibroGen and Its Peers in April 2018

    FibroGen (FGEN) is a biopharmaceutical company involved in the discovery and development of first-in-class therapeutics. The drug is in Phase 3 of development for the treatment of anemia in chronic kidney disease. The company has adopted a global approach to the development and commercialization of its product candidates.

  • Analysts’ Ratings for Intercept Pharmaceuticals in April
    Market Realist3 months ago

    Analysts’ Ratings for Intercept Pharmaceuticals in April

    Intercept Pharmaceuticals (ICPT) is a biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of viral, progressive liver diseases utilizing its proprietary bile acid chemistry. Of the 20 analysts covering Intercept Pharmaceuticals in April 2018, ten of them have given the stock a “buy” or higher rating. Seven analysts have given it a “hold,” and three have given it a “sell.” The mean rating for the stock is 2.5 with a target price of $110.91.

  • Are Options Traders Betting on a Big Move in Conatus (CNAT) Stock?
    Zacks3 months ago

    Are Options Traders Betting on a Big Move in Conatus (CNAT) Stock?

    Investors in Conatus Pharmaceuticals (CNAT) need to pay close attention to the stock based on moves in the options market lately.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Intercept Pharmaceuticals and Conatus Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / April 6, 2018 / Shares of biotech stock Intercept headed higher on Thursday after the company announced that it had priced its upsized underwritten public offering. Shares of ...

  • Conatus' Emricasan Fails in Phase II Study, Shares Sink
    Zacks3 months ago

    Conatus' Emricasan Fails in Phase II Study, Shares Sink

    Conatus Pharmaceuticals' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on liver transplant patients with fibrosis or cirrhosis.

  • Market Exclusive3 months ago

    Here’s What’s Moving Conatus And Paratek

    Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has taken a real hit heading into the latter half of this week on some fresh trial data. The company fell more than 33% during the session on Wednesday, closing out at $4.01 a share on a substantial multiplier of its average daily volume. So what happened? As noted, the action […] The post Here’s What’s Moving Conatus And Paratek appeared first on Market Exclusive.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Trending Tickers: Conatus Pharmaceuticals and bluebird bio

    NEW YORK, NY / ACCESSWIRE / April 5, 2018 / After falling sharply on global trade fears in early trading Wednesday, U.S. stocks rallied to close in the green. The Dow Jones Industrial Average touched a ...

  • What Spooked Conatus Pharmaceuticals (CNAT) Investors This Evening
    SmarterAnalyst3 months ago

    What Spooked Conatus Pharmaceuticals (CNAT) Investors This Evening

    A lottery ticket, however, costs only a buck or two, while getting a biotech company wrong can hurt a lot more than that. Case in point: Conatus Pharmaceuticals (NASDAQ:CNAT) shares are diving over 25% in after-hours trading Wednesday, after the drug maker announced that POLT-HCV-SVR, the company’s exploratory Phase 2b POLT-HCV-SVR proof-of-concept clinical trial, did not meet its primary endpoint. POLT-HCV-SVR, initiated in the second quarter of 2014, in approximately 60 post-orthotopic liver transplant (POLT) recipients with liver fibrosis or cirrhosis post-transplant as a result of recurrent HCV infection who have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy.

  • MarketWatch3 months ago

    Conatus Pharma shares fall on liver-drug study data

    Conatus Pharmaceuticals Inc. shares dropped in the extended session after the biotech company said a clinical study of its liver disease treatment did not reach its goals. Conatus shares, which had been ...